GEP20094738B - Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2) - Google Patents
Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)Info
- Publication number
- GEP20094738B GEP20094738B GEAP200610441A GEAP2006010441A GEP20094738B GE P20094738 B GEP20094738 B GE P20094738B GE AP200610441 A GEAP200610441 A GE AP200610441A GE AP2006010441 A GEAP2006010441 A GE AP2006010441A GE P20094738 B GEP20094738 B GE P20094738B
- Authority
- GE
- Georgia
- Prior art keywords
- benzoyl derivative
- treatment
- aminocarbazole
- pge2
- prostaglandin
- Prior art date
Links
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 title abstract 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title 1
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 2
- 206010037660 Pyrexia Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 230000003449 preventive effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000909A ITMI20050909A1 (it) | 2005-05-19 | 2005-05-19 | Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2- |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20094738B true GEP20094738B (en) | 2009-07-27 |
Family
ID=35219704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP200610441A GEP20094738B (en) | 2005-05-19 | 2006-05-03 | Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2) |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8686021B2 (https=) |
| EP (1) | EP1881826B1 (https=) |
| JP (1) | JP5086991B2 (https=) |
| KR (1) | KR101312579B1 (https=) |
| CN (1) | CN101166528B (https=) |
| AR (1) | AR054126A1 (https=) |
| AT (1) | ATE473739T1 (https=) |
| AU (1) | AU2006246688B2 (https=) |
| BR (1) | BRPI0609718A2 (https=) |
| CA (1) | CA2604562C (https=) |
| DE (1) | DE602006015457D1 (https=) |
| DK (1) | DK1881826T3 (https=) |
| EA (1) | EA012724B1 (https=) |
| ES (1) | ES2347174T3 (https=) |
| GE (1) | GEP20094738B (https=) |
| IL (1) | IL186072A (https=) |
| IT (1) | ITMI20050909A1 (https=) |
| MX (1) | MX2007013491A (https=) |
| PL (1) | PL1881826T3 (https=) |
| PT (1) | PT1881826E (https=) |
| SI (1) | SI1881826T1 (https=) |
| UA (1) | UA94044C2 (https=) |
| WO (1) | WO2006122680A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20051523A1 (it) | 2005-08-03 | 2007-02-04 | Acraf | Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo |
| EP2119705A1 (en) | 2008-05-14 | 2009-11-18 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor |
| US8792839B2 (en) | 2009-05-14 | 2014-07-29 | Qualcomm Incorporated | Allocating transmit power among multiple air interfaces |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241368A (ja) * | 1997-02-18 | 2002-08-28 | Shionogi & Co Ltd | 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物 |
| WO2001007409A1 (en) | 1999-07-23 | 2001-02-01 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| US6399631B1 (en) | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
| CA2381111A1 (en) * | 1999-08-26 | 2001-03-01 | Leah M. Giupponi | Npy antagonists: spiroisoquinolinone derivatives |
| DE10125961A1 (de) * | 2001-05-29 | 2002-12-12 | Boehringer Ingelheim Int | Carbazolderivate und deren Verwendung zur Herstellung einer Arzneimittelzusammensetzung zur Behandlung von im Zusammenhang mit NPY stehenden Leiden |
| CA2403307A1 (en) * | 2001-10-23 | 2003-04-23 | Neurogen Corporation | Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives |
| KR20030042344A (ko) * | 2001-11-22 | 2003-05-28 | 한국생명공학연구원 | 에레모필란계 화합물 또는 곰취추출물을 유효성분으로함유하는 염증질환 치료제, 면역질환 치료제, 및 암 치료제 |
| ES2193875B2 (es) * | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
| KR100402714B1 (ko) * | 2002-12-23 | 2003-11-13 | 한국생명공학연구원 | 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도 |
-
2005
- 2005-05-19 IT IT000909A patent/ITMI20050909A1/it unknown
-
2006
- 2006-05-03 US US11/909,393 patent/US8686021B2/en not_active Expired - Fee Related
- 2006-05-03 JP JP2008511591A patent/JP5086991B2/ja not_active Expired - Fee Related
- 2006-05-03 CN CN2006800144162A patent/CN101166528B/zh not_active Expired - Fee Related
- 2006-05-03 ES ES06753538T patent/ES2347174T3/es not_active Expired - Lifetime
- 2006-05-03 UA UAA200713598A patent/UA94044C2/ru unknown
- 2006-05-03 EA EA200702534A patent/EA012724B1/ru not_active IP Right Cessation
- 2006-05-03 SI SI200630781T patent/SI1881826T1/sl unknown
- 2006-05-03 AT AT06753538T patent/ATE473739T1/de active
- 2006-05-03 PT PT06753538T patent/PT1881826E/pt unknown
- 2006-05-03 DK DK06753538.5T patent/DK1881826T3/da active
- 2006-05-03 GE GEAP200610441A patent/GEP20094738B/en unknown
- 2006-05-03 WO PCT/EP2006/004348 patent/WO2006122680A1/en not_active Ceased
- 2006-05-03 BR BRPI0609718-9A patent/BRPI0609718A2/pt not_active IP Right Cessation
- 2006-05-03 DE DE602006015457T patent/DE602006015457D1/de not_active Expired - Lifetime
- 2006-05-03 PL PL06753538T patent/PL1881826T3/pl unknown
- 2006-05-03 CA CA2604562A patent/CA2604562C/en not_active Expired - Fee Related
- 2006-05-03 MX MX2007013491A patent/MX2007013491A/es active IP Right Grant
- 2006-05-03 KR KR1020077029661A patent/KR101312579B1/ko not_active Expired - Fee Related
- 2006-05-03 EP EP06753538A patent/EP1881826B1/en not_active Expired - Lifetime
- 2006-05-03 AU AU2006246688A patent/AU2006246688B2/en not_active Ceased
- 2006-05-17 AR ARP060101981A patent/AR054126A1/es not_active Application Discontinuation
-
2007
- 2007-09-19 IL IL186072A patent/IL186072A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200702534A1 (ru) | 2008-04-28 |
| AU2006246688B2 (en) | 2011-09-22 |
| UA94044C2 (ru) | 2011-04-11 |
| AU2006246688A1 (en) | 2006-11-23 |
| BRPI0609718A2 (pt) | 2011-10-18 |
| KR101312579B1 (ko) | 2013-09-30 |
| MX2007013491A (es) | 2008-01-24 |
| US20080287518A1 (en) | 2008-11-20 |
| KR20080018898A (ko) | 2008-02-28 |
| EA012724B1 (ru) | 2009-12-30 |
| SI1881826T1 (sl) | 2010-10-29 |
| CA2604562C (en) | 2013-09-17 |
| PL1881826T3 (pl) | 2010-12-31 |
| ATE473739T1 (de) | 2010-07-15 |
| EP1881826B1 (en) | 2010-07-14 |
| ITMI20050909A1 (it) | 2006-11-20 |
| CN101166528A (zh) | 2008-04-23 |
| ES2347174T3 (es) | 2010-10-26 |
| DE602006015457D1 (de) | 2010-08-26 |
| CN101166528B (zh) | 2011-06-15 |
| IL186072A0 (en) | 2008-08-07 |
| PT1881826E (pt) | 2010-08-05 |
| DK1881826T3 (da) | 2010-11-01 |
| CA2604562A1 (en) | 2006-11-23 |
| JP5086991B2 (ja) | 2012-11-28 |
| IL186072A (en) | 2012-05-31 |
| HK1119571A1 (en) | 2009-03-13 |
| AR054126A1 (es) | 2007-06-06 |
| JP2008540591A (ja) | 2008-11-20 |
| WO2006122680A1 (en) | 2006-11-23 |
| EP1881826A1 (en) | 2008-01-30 |
| US8686021B2 (en) | 2014-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024000208A (es) | Restos de administracion terapeutica novedosos y usos de estos. | |
| MX2012005131A (es) | Enfoques terapeuticos nuevos para tratar la enfermedad de alzheimer. | |
| NO20071267L (no) | Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer | |
| WO2008103472A3 (en) | Prevention and treatment of synucleinopathic and amyloidogenic disease | |
| EA201071244A1 (ru) | Новые терапевтические подходы в лечении болезни альцгеймера и обусловленных ею расстройств посредством модуляции ангиогенеза | |
| UA102541C2 (uk) | Сполука 3-амінокарбазолу, фармацевтична композиція, яка її містить, та спосіб її одержання | |
| TWI369982B (en) | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment | |
| WO2010036460A3 (en) | Anti-cd147 antibodies, methods, and uses | |
| MX2007001679A (es) | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. | |
| UA99309C2 (ru) | Замещенные пиперидинодигидротиенопиримидины | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| WO2007127474A3 (en) | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| SG166820A1 (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| TW200724541A (en) | Imidazoquinolines as lipid kinase inhibitors | |
| EA200970287A1 (ru) | Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты | |
| NO20084531L (no) | Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser | |
| CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
| EA201171087A1 (ru) | СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ | |
| SE0400184D0 (sv) | New therapeutical use | |
| MX2008013635A (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. | |
| WO2008066626A3 (en) | METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR | |
| PL2244703T3 (pl) | Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii | |
| EP1781277A4 (en) | COMBINATION PREPARATION | |
| SG158863A1 (en) | Intravenous formulations of pde-5 inhibitors |